Sakar Healthcare Ltd

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 02 September 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 13 September 2026, providing investors with the latest comprehensive analysis.

Sakar Healthcare Ltd has demonstrated a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is supported by a blend of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling potential upside for investors amid a strong price performance that outpaces the broader market.

A 192.61% stock return in one year. An 82.3% growth in net profit over the same period. The gap between those two numbers — roughly 110 percentage points — is driven largely by the market’s willingness to pay a significantly higher multiple for each rupee of Sakar Healthcare Ltd’s earnings. That divergence is the central story behind this micro-cap’s multibagger status.

Sakar Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 September 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sakar Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Sakar Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a 3.36% gain on 18 Aug 2026, the stock’s technical indicators present a mixed picture, with some suggesting caution while others confirm underlying strength. This article analyses the recent price momentum, key technical signals, and the implications for investors amid a backdrop of strong long-term returns.

Sakar Healthcare Ltd has experienced a notable shift in price momentum, with technical indicators signalling a transition from a mildly bullish to a bullish trend. The stock’s recent surge, supported by robust moving averages and positive MACD readings, underscores growing investor confidence in this micro-cap pharmaceutical player.

Sakar Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 August 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Sakar Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, transitioning from a bullish to a mildly bullish trend. Despite a slight dip in its share price, the stock’s technical indicators present a complex picture, with some signals pointing to sustained strength while others suggest caution for investors.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 July 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Sakar Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by a mix of technical indicator signals, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest an improving price momentum and potential for further upside in the near term.

Sakar Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent day decline of 3.07%, the stock’s year-to-date return of 96.04% significantly outpaces the Sensex’s negative 9.04% return, signalling underlying strength amid mixed technical indicators.

Sakar Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a marked improvement in its financial performance for the quarter ended June 2026. The company’s recent results reveal robust revenue growth, significant margin expansion, and improved return ratios, signalling a very positive shift in its financial trend despite a recent downgrade in its Mojo Grade from Buy to Hold.

Sakar Healthcare Ltd., a Gujarat-based pharmaceutical manufacturer, delivered robust top-line growth in Q1 FY27 with net sales rising 38.36% year-on-year to ₹72.97 crores, though net profit growth of 120.13% to ₹10.28 crores came with a sequential dip of 6.72%. The stock, trading at ₹802.20 with a market capitalisation of ₹1,903 crores, has declined 3.07% following the results announcement, reflecting investor concerns about margin compression despite the strong revenue momentum.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 15 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 July 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 15 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 09 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.